Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (NASDAQ: LTRN) expanded predictBBB.ai into a real-time Large Quantitative Model (LQM) delivered as a web service for small-molecule developability profiling. By submitting a single SMILES string users get a 360-degree profile in seconds across 99 molecular features, with five algorithms ranking in the top 12 on the Therapeutic Data Commons leaderboard. The LQM is integrated into withZeta.ai, supports high-throughput screening, and is offered under a planned subscription roadmap with API access in development; Lantern is inviting early collaboration with pharma partners.
Lantern Pharma (NASDAQ: LTRN) will publicly demonstrate withZeta.ai, its multi‑agentic AI co‑scientist platform, on April 30, 2026 with two live sessions at 8:30 AM ET and 4:30 PM ET.
The platform, publicly shown after debuts at Nasdaq MarketSite and AACR 2026, executes real‑time multi‑database research workflows and offers subscription tiers aimed at rare cancer research and commercial users.
Lantern Pharma (NASDAQ: LTRN) scheduled a mid‑May 2026 Type C meeting with the FDA to seek protocol amendments to its Phase 2 HARMONIC trial of LP-300. Emerging data (cutoff April 13, 2026) show an 8.3‑month mPFS in EGFR Exon 21 L858R patients (n=16) with no added toxicity versus chemotherapy.
Lantern proposes focusing enrollment on L858R, converting to a Simon two‑stage single‑arm Phase 2, and increasing LP-300 cycles from 6 to 8 to further evaluate durability and safety.
Lantern Pharma (Nasdaq: LTRN) launched withZeta.ai, the world’s first multi-agentic AI co-scientist for rare cancer drug discovery, now available with introductory, academic, and commercial subscriptions.
Commercial subscriptions are live at withzeta.ai, with debut demos at Nasdaq MarketSite on April 16, 2026 and AACR 2026 (Booth 5054) April 17–22. The platform leverages Lantern’s RADR knowledge-base covering 438 cancer types, claims a PredictBBB.ai 94.1% accuracy, and builds on three drugs in clinical trials, >100 patients dosed, and 12 FDA designations.
Lantern Pharma (Nasdaq: LTRN) will host a live investor and analyst briefing on April 9, 2026 at 8:30 AM ET featuring a demonstration of withZeta.ai, a multi-agentic AI co-scientist for rare cancer drug discovery, development, and trial design.
The webcast will cover platform capabilities, commercial subscription model, competitive positioning, and near-term revenue strategy. Lantern cites 12 FDA designations, three drugs in precision oncology trials and over 100 patients dosed as part of the platform’s clinical heritage.
Lantern Pharma (NASDAQ: LTRN) reported 2025 operational and financial results, highlighting clinical progress across LP-300, LP-184, LP-284 and IND clearance for STAR-001, RADR® platform expansion and launch of withZeta.ai.
Key metrics: $10.1M cash at year-end, 48% LP-184 clinical benefit rate at therapeutic doses, LP-300 safety lead-in showing 86% clinical benefit and 43% objective response in initial U.S. patients.
Lantern Pharma (NASDAQ: LTRN) confirmed that Panna Sharma remains President, CEO, and director after a false third‑party article claimed he stepped down. The board affirmed confidence, cited a recently cleared IND for STAR-001 pediatric CNS trial, and warned of potential market manipulation while investigating and considering legal and regulatory referrals.
The company reiterated reliance on official SEC filings and its investor site and noted a webcast on March 30, 2026 at 4:30 p.m. ET to review FY2025 results.
Lantern Pharma (NASDAQ: LTRN) and Starlight Therapeutics announced FDA clearance of IND No. 179145 to initiate a planned Phase 1 pediatric CNS trial of STAR-001 (LP-184). The multicenter study will test STAR-001 as monotherapy and with spironolactone across relapsed/refractory ATRT, DIPG, GBM, medulloblastoma, and ependymoma, enrolling ~18–42 patients at POETIC sites. Preclinical data showed ERCC3 protein reduction ≥50% and a combination survival benefit (median 27 to 76 days, +181%, p=0.0018). Trial initiation is subject to additional funding.
Lantern Pharma (NASDAQ: LTRN) will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 2026 at 4:30 p.m. ET.
Management will discuss results for the period ended December 31, 2025, upcoming milestones, clinical trials, and developments of the RADR® AI platform. A replay will be available on the investor relations website.
Lantern Pharma (NASDAQ: LTRN) announced that CEO and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit in Boston on February 17–19, 2026. The presentation is scheduled for February 19, 2026 at 10:30 a.m. ET.
Lantern will describe how its RADR AI platform supported development of STAR-001/LP-184, creation of subsidiary Starlight Therapeutics, and work on CNS cancers including recurrent glioblastoma and pediatric ATRT. STAR-001 has FDA Orphan Drug and Rare Pediatric Disease designations.